SDIX (Nasdaq: SDIX), a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, today reported financial results for the quarter ended March 31, 2012.

Revenue for the first quarter of 2012 was $5.6 million, decreasing from $6.6 million for the same period in 2011. This decrease was primarily related to the timing of IVD sales, a softening biopharmaceutical market, and external regulatory changes in the food industry.

Net loss for the first quarter of 2012 was $1.2 million, compared to a net loss of $658,000 for the same period in 2011. Net loss for the first quarter of 2011 included income from discontinued operations of $388,000.

The Company also announced that it has established a collaborative relationship with a top 10 pharmaceutical company with the goal of utilizing the advanced Genomic Antibody Technology (“GAT™”) platform to generate monoclonal antibodies against a GPCR target. The advanced GAT™ platform, which builds on SDIX’s antibody generation capabilities, has been shown in internal studies to be effective in raising diverse collections of monoclonal antibodies against GPCR targets. SDIX will employ its advanced GAT™ platform for the discovery of monoclonal antibodies against a specific GPCR target chosen by its collaborator. Resulting antibodies are expected to be incorporated into a clinical assay that is considered essential to this pharmaceutical company’s development of a novel therapeutic.

Regarding the collaboration, Francis M. DiNuzzo, President and CEO of SDIX, stated, “The initiation of this collaboration marks an important step forward for SDIX. We are pleased to have progressed our advanced GAT™ system to the point where pharmaceutical and biotechnology companies are willing to collaborate with us, using our technology to develop monoclonal antibodies against critical targets.” Klaus Lindpaintner, Vice President of Research and CSO for SDIX, went on to say, “We believe our advanced GAT™ system can establish a new paradigm in monoclonal antibody development for difficult targets such as GPCRs.” He added, “This collaboration offers us the opportunity to demonstrate our capabilities with a well-regarded antibody development group within a major pharmaceutical company. We expect to be successful in providing our collaborator with antibodies they have so far been unable to generate."

Commenting on the core business, Mr. DiNuzzo said, “We are taking aggressive actions in our core Life Science business to increase our order flow and believe these actions will allow us to achieve higher revenue as the year progresses. In Food Safety, we are focused on growing our Salmonella and Listeria products, and continue to drive our international market expansion. Food Safety revenue increased over the fourth quarter of 2011 and we believe the improvement will continue in subsequent quarters.”

Financials

Gross profit for the first quarter of 2012 was $3.2 million, as compared to $3.6 million for the same period in 2011. Gross margins were 57% for the first quarter of 2012, compared to 56% for the same period in 2011. The revenue from our February 2012 agreement with Becton Dickinson’s BD Diagnostics business unit contributed approximately $900,000 in gross margin during the quarter.

First quarter operating expenses were $4.4 million, a decrease of $303,000 compared to the first quarter of 2011. The overall decrease in SG&A expenses offset the planned R&D investments in SDIX’s next generation GAT™ platform, which increased to $1.1 million from $863,000 in the first quarter of 2011.

Loss from continuing operations for the first quarter was $1.2 million in 2012, as compared with $1.0 million in 2011. Net loss for the first quarter of 2012 was $1.2 million, or $0.06 per diluted share, compared to a net loss of $658,000, or $0.03 per diluted share, for the same period in 2011.

Life Science Revenues

Life Science revenue decreased to $4.0 million for the first quarter of 2012, as compared to $4.5 million for the same period in 2011. This decrease was primarily related to order timing in the IVD business where large orders from customers result in quarter to quarter variability, coupled with a softer market in the biopharmaceutical area. This was partially offset by $920,000 of revenue from the BD agreement.

Kit Revenues

Food Safety revenue decreased 18%, to $1.5 million, for the first quarter of 2012, as compared to $1.8 million for the same period in 2011. The decrease is primarily attributable to regulatory changes that have moved a number of our customers away from SDIX’s E-coli products to other testing solutions.

As the Company continued to shift focus away from the Ag-GMO business, revenue for the quarter decreased by $81,000 to $180,000.

Balance Sheet

The Company completed the first quarter 2012 with cash and restricted cash of $10.0 million and stockholders’ equity of $19.0 million.

Conference Call

The dial-in number for the live conference call at 4:30PM ET today will be 877-407-8035 (201-689-8035 outside the U.S.). A live webcast of the conference call will be available on the Company’s website, www.sdix.com, as well as www.investorcalendar.com. For those who cannot listen to the live broadcast, an audio replay of the call will be available on each of these websites for 90 days. Telephone replays of the call will be available from 7:30 p.m. ET on May 10, 2012 through 11:59 p.m. ET on May 24, 2012. To listen to the telephone replay, dial 877-660-6853 (201-612-7415 outside the U.S.) and enter account number 286 and conference ID 394108.

About SDIX (www.sdix.com)

SDIX is a biotechnology company with a core expertise in creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.

In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs and provide antibodies and assays for the diagnosis of disease. In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost-effective results.

This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “can”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.